1st Floor 24 Hills Road Cambridge CB2 1JP, UK P 01223 855340W elifesciences.org

T @elife

# eLife's transparent reporting form

We encourage authors to provide detailed information within their submission to facilitate the interpretation and replication of experiments. Authors can upload supporting documentation to indicate the use of appropriate reporting guidelines for health-related research (see <a href="EQUATOR Network">EQUATOR Network</a>), life science research (see the <a href="BioSharing Information">BioSharing Information</a> Resource), or the <a href="ARRIVE guidelines">ARRIVE guidelines</a> for reporting work involving animal research. Where applicable, authors should refer to any relevant reporting standards documents in this form.

If you have any questions, please consult our Journal Policies and/or contact us: editorial@elifesciences.org.

## Sample-size estimation

- You should state whether an appropriate sample size was computed when the study was being designed
- You should state the statistical method of sample size computation and any required assumptions
- If no explicit power analysis was used, you should describe how you decided what sample (replicate) size (number) to use

Please outline where this information can be found within the submission (e.g., sections or figure legends), or explain why this information doesn't apply to your submission:

Sample size calculations can be found in Supplementary Table 2.

In the manuscript we've included the following: "Statistical power was calculated using an online calculator for MR available at: https://shiny.cnsgenomics.com/mRnd/. Calculations were performed separately for each clock-cancer combination. They were based on a type 1 error rate of 0.05, the proportion of phenotypic variance explained by genetic variants (R2) for each measure of epigenetic age acceleration, and the total number of cases and controls included in the meta-analysis for each cancer. Across combinations of the four epigenetic clock acceleration and five cancer measures, we had 80% power to detect ORs as small as 1.04–1.39 (Supplementary Table 2)."

# **Replicates**

- You should report how often each experiment was performed
- You should include a definition of biological versus technical replication
- The data obtained should be provided and sufficient information should be provided to indicate the number of independent biological and/or technical replicates
- If you encountered any outliers, you should describe how these were handled
- Criteria for exclusion/inclusion of data should be clearly stated
- High-throughput sequence data should be uploaded before submission, with a private link for reviewers provided (these are available from both GEO and ArrayExpress)

Please outline where this information can be found within the submission (e.g., sections or figure legends), or explain why this information doesn't apply to your submission:

1st Floor 24 Hills Road Cambridge CB2 1JP, UK P 01223 855340W elifesciences.org

T @elife

Not applicable. This is a Mendelian randomization study, not an experiment.

# **Statistical reporting**

- Statistical analysis methods should be described and justified
- Raw data should be presented in figures whenever informative to do so (typically when N per group is less than 10)
- For each experiment, you should identify the statistical tests used, exact values of N, definitions of center, methods of multiple test correction, and dispersion and precision measures (e.g., mean, median, SD, SEM, confidence intervals; and, for the major substantive results, a measure of effect size (e.g., Pearson's r, Cohen's d)
- Report exact p-values wherever possible alongside the summary statistics and 95% confidence intervals. These should be reported for all key questions and not only when the p-value is less than 0.05.

Please outline where this information can be found within the submission (e.g., sections or figure legends), or explain why this information doesn't apply to your submission:

Statistical methods have been described in pages 9-14. Summary statistics used for epigenetic age acceleration are available in Supplementary Table 1. Results have been reported in pages 15-23, Supplementary Tables 3-11 and Supplementary Figures 1-7.

(For large datasets, or papers with a very large number of statistical tests, you may upload a single table file with tests, Ns, etc., with reference to sections in the manuscript.)

#### **Group allocation**

- Indicate how samples were allocated into experimental groups (in the case of clinical studies, please specify allocation to treatment method); if randomization was used, please also state if restricted randomization was applied
- Indicate if masking was used during group allocation, data collection and/or data analysis

Please outline where this information can be found within the submission (e.g., sections or figure legends), or explain why this information doesn't apply to your submission:

Not applicable. This is a Mendelian randomization study, so we did not allocate individuals into experimental groups. Genetic variants were used as proxies for epigenetic age acceleration measures. Data were obtained from a published genomewide association study by McCartney et al.

## Additional data files ("source data")

- We encourage you to upload relevant additional data files, such as numerical data that are represented as a graph in a figure, or as a summary table
- Where provided, these should be in the most useful format, and they can be uploaded as "Source data" files linked to a main figure or table
- Include model definition files including the full list of parameters used
- Include code used for data analysis (e.g., R, MatLab)
- Avoid stating that data files are "available upon request"

Please indicate the figures or tables for which source data files have been provided:



1st Floor 24 Hills Road Cambridge CB2 1JP, UK P 01223 855340W elifesciences.orgT @elife

Code used for the data analyses is available at: <a href="https://github.com/fernandam93/epiclocks">https://github.com/fernandam93/epiclocks</a> cancer